Korean Circ J.  2025 Mar;55(3):248-250. 10.4070/kcj.2024.0424.

Epigenetic Modulation in Heart Failure: HDAC Inhibitors as Emerging Therapeutic Allies

• Choi JO

• KMID: 2565816
• DOI: http://doi.org/10.4070/kcj.2024.0424

Reference

1. Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Int J Heart Fail. 2023; 5:66–81. PMID: 37180564.

2. Lee CJ, Lee H, Yoon M, et al. Heart failure statistics 2024 update: a report from the Korean Society of Heart Failure. Int J Heart Fail. 2024; 6:56–69. PMID: 38694933.

3. McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018; 138:183–211. PMID: 29551127.

4. Li P, Ge J, Li H. Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease. Nat Rev Cardiol. 2020; 17:96–115. PMID: 31350538.

5. Zhou H, Kee HJ, Wan L, et al. YAK577 attenuates cardiac remodeling and fibrosis in isoproterenol-infused heart failure mice by downregulating MMP12. Korean Circ J. 2025; 55:231–247. PMID: 39601396.

6. Yang F, Zhao N, Ge D, Chen Y. Next-generation of selective histone deacetylase inhibitors. RSC Advances. 2019; 9:19571–19583. PMID: 35519364.

7. Yoon S, Eom GH. HDAC and HDAC inhibitor: from cancer to cardiovascular diseases. Chonnam Med J. 2016; 52:1–11. PMID: 26865995.

8. Ho JSY, Jou E, Khong PL, Foo RSY, Sia CH. Epigenetics in heart failure. Int J Mol Sci. 2024; 25:12010. PMID: 39596076.

9. Bagchi RA, Weeks KL. Histone deacetylases in cardiovascular and metabolic diseases. J Mol Cell Cardiol. 2019; 130:151–159. PMID: 30978343.

10. Zhao T, Kee HJ, Kee SJ, Jeong MH. Hdac8 inhibitor alleviates transverse aortic constriction-induced heart failure in mice by downregulating Ace1. Oxid Med Cell Longev. 2022; 2022:6227330. PMID: 35126818.